[HTML][HTML] Ischaemic Stroke, Thromboembolism and Clot Structure
K Stanton, H Philippou, RAS Ariëns - Neuroscience, 2024 - Elsevier
Ischaemic stroke is a major cause of morbidity and mortality worldwide. Blood clotting and
thromboembolism play a central role in the pathogenesis of ischaemic stroke. An increasing …
thromboembolism play a central role in the pathogenesis of ischaemic stroke. An increasing …
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke
A Marè, S Lorenzut, F Janes, C Gentile… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction The drug most frequently used for thrombolysis in cases of acute ischemic
stroke (AIS) is alteplase. However, there is moderate-to-high-quality evidence that …
stroke (AIS) is alteplase. However, there is moderate-to-high-quality evidence that …
Multicenter exploration of tenecteplase transition factors: A quantitative analysis
S Prasad, EM Jones, M Gebreyohanns, Y Kwon… - Journal of Stroke and …, 2024 - Elsevier
Background Tenecteplase (TNK) is gaining recognition as a novel therapy for acute
ischemic stroke (AIS). Despite TNK offering a longer half-life, time and cost saving benefits …
ischemic stroke (AIS). Despite TNK offering a longer half-life, time and cost saving benefits …
[HTML][HTML] Support for Thrombolytic Therapy for Acute Stroke Patients on Direct Oral Anticoagulants: Mortality and Bleeding Complications
P Koscumb, L Murphy, M Talbott, S Nuti… - Western Journal of …, 2024 - ncbi.nlm.nih.gov
Background Alteplase (tPA) is the initial treatment for acute ischemic stroke. Current tPA
guidelines exclude patients who took direct oral anticoagulants (DOAC) within the prior 48 …
guidelines exclude patients who took direct oral anticoagulants (DOAC) within the prior 48 …
[HTML][HTML] Tenecteplase
KT Bach, F Lui - 2023 - europepmc.org
Objectives: Identify the indications for initiating therapy with tenecteplase. Implement the
appropriate monitoring strategy for tenecteplase. Assess the potential adverse event profile …
appropriate monitoring strategy for tenecteplase. Assess the potential adverse event profile …
[HTML][HTML] Risk of suicide and self-harm following gender-affirmation surgery
JJ Straub, KK Paul, LG Bothwell, SJ Deshazo… - Cureus, 2024 - ncbi.nlm.nih.gov
Methods This retrospective study utilized de-identified patient data from the TriNetX (TriNetX,
LLC, Cambridge, MA) database, involving 56 United States healthcare organizations and …
LLC, Cambridge, MA) database, involving 56 United States healthcare organizations and …
[HTML][HTML] D-dimer as a Rule-Out for Aortic Dissection
JM Carter, RB Tom, R Sunesra, NJ Bilby, B Mireles… - Cureus, 2023 - ncbi.nlm.nih.gov
Methods This study utilizes the TriNetX database (https://trinetx. com/), encompassing data
from 54 healthcare organizations across the United States over the past two decades from …
from 54 healthcare organizations across the United States over the past two decades from …
[PDF][PDF] Effects of Serum Potassium on Mortality in Patients With ST-Elevation Myocardial Infarction
CJ Jensen, JK Nielsen, MM Talbott, D O'Connell… - Cureus, 2024 - cureus.com
Introduction: Disturbances in potassium levels can induce ventricular arrhythmias and
heighten mortality in patients with ST-elevation myocardial infarction (STEMI). This study …
heighten mortality in patients with ST-elevation myocardial infarction (STEMI). This study …
[HTML][HTML] Comparación entre tenecteplase y alteplase en la trombolisis intravenosa del ataque cerebrovascular isquémico
I Rodríguez, P Grille, A Deicas - Revista Médica del Uruguay, 2024 - scielo.edu.uy
Introducción: la trombolisis intravenosa es parte fundamental del tratamiento agudo de los
pacientes que sufren un ataque cerebrovascular (ACV) isquémico. Existe un interés …
pacientes que sufren un ataque cerebrovascular (ACV) isquémico. Existe un interés …
[HTML][HTML] Bicarbonate and Serum Lab Markers as Predictors of Mortality in the Trauma Patient
MM Talbott, AN Waguespack… - Western Journal of …, 2024 - escholarship.org
Methods: This retrospective, propensity-matched cohort study used the TriNetX database,
covering approximately 92 million patients from 55 healthcare organizations in the United …
covering approximately 92 million patients from 55 healthcare organizations in the United …